FDA 483 - Gilead Sciences, Inc. - February 12, 2024

An FDA inspection of Gilead Sciences, Inc. in La Verne, CA, identified a significant deficiency in their manufacturing record-keeping practices. The firm failed to include unique identifiers for major equipment used in the production of drug product batches, specifically for AmBisome. This indicates a lapse in maintaining adequate batch production and control records.